510(k) Report

510(k) · Cleared

Cleared

Carbamazepine, Valproic Acid, TDM Calibration Set B and Abtrol, Nortrol Controls

K063131510(k) TraditionalCleared Oct 5, 2007357-day reviewClass II21 CFR 862.3645

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Thermo Electron OY · KLT Enzyme Immunoassay, Carbamazepine

Cleared on Oct 5, 2007 after a 357-day review. The FDA summary names its predicate without a number.

Decided
Oct 5, 2007
Review
357 days
Class
Class II
Product code
KLT
Recalls
None
Predicates
0

The FDA summary names its predicate without a number.

FIG. 1 — Lineage of K063131Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KLT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—CEDIA Carbamazepine II
Named without a submission number
—
*—CEDIA Valproic acid II
Named without a submission number
—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All KLT devices

KLT Enzyme Immunoassay, Carbamazepine: FDA decisions, review times, recalls and adverse event reports over 20 years. 2007, this device’s year, is highlighted.

FDA decisions per year · KLT

1in 2015

2007: 12011: 12013: 12015: 1
2007high 1 (2007) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KLT

Too few KLT 510(k)s in any year since 2007 to give a median.

Recalls per year · KLT

1in 2013

2013: 1
2007high 1 (2013) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · KLT

4in 2025

2009: 22010: 12011: 12012: 12013: 12014: 32015: 92016: 32017: 12018: 42019: 62020: 12021: 22022: 72023: 32024: 12025: 4
2007high 9 (2015) · low 0 (2007)2025

MAUDE reports naming product code KLT, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—00
20080—00
20090—02
20100—01
20111—01
20120—01
20131—11
20140—03
20151—09
20160—03
20170—01
20180—04
20190—06
20200—01
20210—02
20220—07
20230—03
20240—01
20250—04
20260—0—

What is it indicated for?

The Carbamazepine is intended for the quantitative in vitro diagnostic determination of the carbamazepine concentration in human serum using T60 Clinical Chemistry Analyzers. Measurements are used in the diagnosis and treatment of carbamazepine overdose and in monitoring levels of carbamazepine to help ensure proper therapy The Valproic Acid is intended for the quantitative in vitro diagnostic determination of the valproic acid concentration in human…

Read the full statement (128 words)

The Carbamazepine is intended for the quantitative in vitro diagnostic determination of the carbamazepine concentration in human serum using T60 Clinical Chemistry Analyzers. Measurements are used in the diagnosis and treatment of carbamazepine overdose and in monitoring levels of carbamazepine to help ensure proper therapy

The Valproic Acid is intended for the quantitative in vitro diagnostic determination of the valproic acid concentration in human serum using T60 Clinical Chemistry Analyzers. Measurements are used in the diagnosis and treatment of valproic acid overdose and in monitoring levels of valproic acid to help ensure proper therapy.

TDM Calibration set B is intended for in vitro diagnostic use as a calibrator in the quantitative measurement of the kit code 981645 Carbamazepine and kit code 981650 Valproic acid assays on T60 Analyzer.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K063131: Carbamazepine, Valproic Acid, TDM Calibration Set B and Abtrol, Nortrol Controls.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K063131

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026